| Ytd | -38.72% | |
| 1y | -50.70% |
| Open | 77.00 | Prev Close | 77.34 | Low | 75.63 | High | 77.19 | Mkt Cap | 31.86B |
| Vol | 5.81M | Avg Vol | 6.49M | EPS | 6.13 | P/E | 12.58 | Forward P/E | 11.81 |
| Beta | 0.73 | Short Ratio | 2.47 | Inst. Own | 100.19% | Dividend | 2.12 | Div Yield | 2.74 |
| Ex Div Date | 07-20 | Earning | 11-03 | 50-d Avg | 75.67 | 200-d Avg | 104.14 | 1yr Est | 96.00 |
Phibro Animal Health's Zoetis MFA acquisition has created a larger animal health platform with stron
Blackhill Capital Inc. cut its stake in shares of Zoetis Inc. (NYSE: ZTS) by 28.8% in the undefined
This whale alert can help traders discover the next big trading opportunities. Whales are entities w
Stifel analyst Jonathan Block maintains Zoetis (NYSE:ZTS) with a Hold and lowers the price target
These stocks have been generous with their dividend increases, and more may be on the way.
Zoetis is navigating the worst drawdown in its stock history, driven by weakening U.S. vet clinic tr
Zoetis' Q2 earnings results were mixed, and the company cut its forward guidance. This has reduced t
Zoetis (ZTS) now trades at just 12x forward earnings, with a nearly 3% dividend yield and gross marg
PARSIPPANY, N.J.--(BUSINESS WIRE)---- $ZTS #animalhealth--Zoetis Inc. today announced that Simparica
The U.S. Food and Drug Administration on Thursday issued an emergency use authorization for Zoetis'
https://www.fda.gov/news-events/press-announcements/fda-issues-emergency-use-authorization-drug-trea
BNP Paribas analyst Navann Ty maintains Zoetis (NYSE:ZTS) with a Outperform and lowers the price
Zoetis (NYSE: ZTS) reported second-quarter revenue of $2.5 billion, flat on a reported basis and dow
Zoetis Inc. (NYSE: ZTS - Get Free Report)'s stock price hit a new 52-week low during mid-day trading
Piper Sandler analyst David Westenberg maintains Zoetis (NYSE:ZTS) with a Neutral and lowers the
U.S. stocks close higher on Friday, with Nasdaq up 300 points and S&P 500 at record high. Benzin
Zoetis NYSE: ZTS reported second-quarter revenue of $2.5 billion, flat on a reported basis and down
UBS analyst Andrea Alfonso maintains Zoetis (NYSE:ZTS) with a Neutral and lowers the price target
JP Morgan analyst Chris Schott maintains Zoetis (NYSE:ZTS) with a Overweight and lowers the price
Zoetis cuts its 2026 outlook as weaker vet traffic, price sensitivity and competition pressure in Co
Zoetis Inc. (NYSE:ZTS) reported second-quarter adjusted earnings of $1.87 per share, beating the con
Zoetis beat second-quarter earnings estimates but missed on revenue, cut 2026 guidance and cited wea
Zoetis Inc. (ZTS) Q2 2026 Earnings Call Transcript
ZTS beats Q2 earnings estimates but misses the same for revenues. The company cuts its 2026 revenue
The headline numbers for Zoetis (ZTS) give insight into how the company performed in the quarter end
Zoetis (ZTS) came out with quarterly earnings of $1.87 per share, beating the Zacks Consensus Estima
Animal health company Zoetis cut its annual forecasts on Thursday after missing Wall Street estimate
Zoetis (NYSE:ZTS) lowers FY2026 Adj EPS guidance from $6.85-$7.00 to $6.15-$6.25 vs $6.88 analyst es
Zoetis (NYSE:ZTS) reported quarterly earnings of $1.87 per share which beat the analyst consensus es
PARSIPPANY, N.J.--(BUSINESS WIRE)---- $ZTS #animalhealth--Zoetis Inc. (NYSE:ZTS), the world's leadin
PARSIPPANY, N.J.--(BUSINESS WIRE)--Zoetis Inc. (NYSE: ZTS) today announced the appointment of James
Michael Burry expands short positions against Nvidia and AI, while piling into de-risked value stock
UBS analyst Andrea Alfonso maintains Zoetis (NYSE:ZTS) with a Neutral and lowers the price target
Morgan Stanley analyst Erin Wright maintains Zoetis (NYSE:ZTS) with a Overweight and lowers the p
Zoetis Inc. (NYSE:ZTS) today announced the commercial launch of Portela® (relfovetmab) in Canada and
The Australian agency is conducting a Phase 2 assessment of Zoetis' $160 million acquisition of
July 15, 2026 records indicate that Representative Byron Donalds filed a sale of Cadence Design Syst
Zoetis Inc. today announced its agreement to acquire VitalRADS, a veterinary teleradiology services
Recombinant vector vaccine protects chickens against Newcastle disease and Marek's disease in a
Barclays analyst Glen Santangelo maintains Zoetis (NYSE:ZTS) with a Equal-Weight and lowers the p
TD Cowen analyst Steve Scala maintains Zoetis (NYSE:ZTS) with a Buy and lowers the price target f
Stifel analyst Jonathan Block maintains Zoetis (NYSE:ZTS) with a Hold and lowers the price target
Cramer says Zoetis has issues. Prefers this stock in animal health industry. Energy Transfer is in a
The health care sector's most oversold stocks are a buying opportunity due to undervalued compan
Get the latest analyst rating changes for top companies on Wall Street, including upgrades and downg
Stifel analyst Jonathan Block maintains Zoetis (NYSE:ZTS) with a Hold and lowers the price target
https://www.fda.gov/animal-veterinary/cvm-updates/fda-issues-emergency-use-authorization-over-counte
Citigroup analyst Daniel Grosslight maintains Zoetis (NYSE:ZTS) with a Buy and lowers the price t